The treatment landscape for NSCLC continues to evolve at a rapid pace with the...
The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies i......
MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a...
MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years. Owing to the lack of......
MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by...
MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The ...
Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy...
Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy with a five-year survival rate of less than 10%. The treatment options for patients with pancreatic cancer are limited t......
Market Outlook Targeted therapies are changing the treatment paradigm for...
Market Outlook Targeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into......
Colorectal cancer is the third-most-common cancer globally and is associated...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by ch...
Coming Soon – July 2019 The incidence of gastroesophageal cancer—...
Coming Soon – July 2019 The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ)...
Market Outlook Non-small-cell lung cancer (NSCLC) is one of the most dynamic...
Market Outlook Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibito......
Coming Soon – November 2019 Prostate cancer is the most common cancer...
Coming Soon – November 2019 Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment...
Chemotherapy remains the standard of care for the treatment of ovarian cancer...
Chemotherapy remains the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, ...
Building on the success of Bristol-Myers Squibb / Ono Pharmaceutical’s PD-1...
Building on the success of Bristol-Myers Squibb / Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, in the recurrent renal cell carcinoma (RCC) setting, combination regimens that include immune...
DRG publishes an updated ovarian cancer forecast: The ovarian cancer...
DRG publishes an updated ovarian cancer forecast: The ovarian cancer therapy market will grow 21.1% a......
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. ...
Coming soon-2019 Hepatocellular carcinoma (HCC) is a primary malignancy of...
Coming soon-2019 Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx......
MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised...
MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience a sudden explosion in market growth. Availability of existing systemic agents......
MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most...
MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of......
Market Outlook Clinical pathways, which establish optimal treatment...
Market Outlook Clinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly preva......
Market Outlook Immune checkpoint inhibitors are revolutionizing the...
Market Outlook Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 201......
Market Outlook Malignant melanoma is the most aggressive and life-...
Market Outlook Malignant melanoma is the most aggressive and life-threatening skin cancer, the incidence of which continues to rise despite recent therapeutic advances.......
